Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Oxford BioMedica acquires novel antibody technology

Jan. 17, 2000

AltaRex in-licenses antibody from NIH for AIT platform

Jan. 14, 2000

Ligand sells Marathon assets to CoPharma

Jan. 14, 2000

Japanese marketing approval no longer sought for Mochida's TNF

Jan. 12, 2000

FDA grants priority review status to Wyeth-Ayerst's therapy for relapsed adult AML

Jan. 11, 2000

New developments announced for AltaRex's ovarian cancer therapy

Jan. 6, 2000

Maxamine granted orphan drug status for AML

Jan. 5, 2000

Cell Genesys receives payment from Japan Tobacco

Jan. 3, 2000

Cel-Sci completes another study in head and neck cancer

Dec. 29, 1999

Impressive early phase II clinical data reported for OvaRex in relapsed ovarian cancer

Dec. 29, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 21, 2026
To viral or not to viral: In vivo CAR T debates delivery tech
BioWorld Science
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
To viral or not to viral: In vivo CAR T debates delivery tech
BioWorld Asia
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
Other news to note for July 22, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...